APA (7th ed.) Citation

Padden-Modi, M., Abdel-Aty, H., Jones, C., Brown, L., Dutey-Magni, P., Yogeswaran, Y., . . . James, N. (2024). 1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT). Annals of Oncology, 35, S999. https://doi.org/10.1016/j.annonc.2024.08.1739

Chicago Style (17th ed.) Citation

Padden-Modi, M., et al. "1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-label Trial in Patients with Metastatic Prostate Cancer (mPC) Starting Androgen Deprivation Therapy (ADT)." Annals of Oncology 35 (2024): S999. https://doi.org/10.1016/j.annonc.2024.08.1739.

MLA (9th ed.) Citation

Padden-Modi, M., et al. "1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-label Trial in Patients with Metastatic Prostate Cancer (mPC) Starting Androgen Deprivation Therapy (ADT)." Annals of Oncology, vol. 35, 2024, p. S999, https://doi.org/10.1016/j.annonc.2024.08.1739.